Omisirge Market Growth Patterns And Forecast Outlook Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Omisirge Market In 2026, And How Will Its Value Evolve By 2030?

The expansion observed during the historic period was primarily driven by a rise in the incidence of hematologic malignancies, the inherent limitations of conventional cord blood transplantation, the early positive clinical outcomes of cell expansion technologies, the increasing adoption of allogeneic stem cell transplants, and the regulatory approvals granted for advanced cell therapies.

The projected growth within the forecast period is attributed to the expansion of personalized cell therapy pipelines, increasing investments in regenerative medicine, wider adoption of advanced transplantation protocols, a growing emphasis on minimizing post-transplant complications, and the broadening of cell therapy manufacturing infrastructure. Concurrently, major trends expected during this period include the rising adoption of expanded cord blood therapies, increasing utilization of ex vivo cell expansion techniques, a heightened focus on achieving faster neutrophil engraftment, the expanding scope of allogeneic HSCT applications, and enhanced manufacturing scalability for cell therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20269&type=smp

What Significant Factors Are Influencing The Omisirge Market Expansion?

The future growth of the omisirge market is expected to be propelled by the increasing demand for personalized treatments. These medical interventions are designed to be specifically tailored to an individual’s genetic, environmental, and lifestyle factors to optimize their effectiveness and minimize side effects. The rise in demand for personalized treatments stems from advancements in genetic research, a greater awareness of individualized healthcare, and the growing understanding that customized therapies provide improved efficacy and fewer side effects compared to conventional one-size-fits-all methods. Omisirge enhances personalized treatments by utilizing its capability to adapt to individual patient needs, targeting specific immune responses, and optimizing therapeutic outcomes based on the unique characteristics of each patient’s cancer profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the escalating demand for personalized treatments is anticipated to drive the growth of the omisirge market.

Which Segment Classifications Are Used In The Omisirge Market Segment Analysis?

The omisirge market covered in this report is segmented –

1) By Clinical Indication: Leukemia, Lymphoma, Myeloma, Other Hematologic Malignancies

2) By Distribution Channel: Direct Sales, Distributors

3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers

Which Trends Are Impacting The Progress Of The Omisirge Market?

Companies operating in the Omisirge market are prioritizing the development of technological advancements, such as omidubicel-onlv, with the aim of increasing transplant efficiency and enhancing patient recovery outcomes. Omidubicel-onlv constitutes an allogeneic, stem-cell-based therapy sourced from umbilical cord blood, specifically engineered to improve cell expansion for faster engraftment. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, gave its approval to Gamida Cell’s Omisirge product, which is intended to optimize stem cell engraftment and mitigate infection risks for transplant recipients. The FDA’s green light for Omisirge introduced an advanced, expanded cord-blood–derived cell therapy designed to accelerate neutrophil recovery and reduce the chance of infection in patients with hematologic malignancies. This therapy offers a more consistent engraftment profile than traditional cord blood, thereby making transplants quicker and clinically safer.

Which Firms Are Contributing To The Omisirge Market Ecosystem?

Major companies operating in the omisirge market are Gamida Cell Ltd.

Get The Full Omisirge Market Report:

https://www.thebusinessresearchcompany.com/report/omisirge-global-market-report

Which Region Holds The Highest Market Share In The Omisirge Market?

North America was the largest region in the omisirge market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Omisirge Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/omisirge-global-market-report

Browse Through More Reports Similar to the Global Omisirge Market 2026, By The Business Research Company

Premium Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/premium-finance-global-market-report

Future Of Cv Depot Charging Market Report 2026

https://www.thebusinessresearchcompany.com/report/future-of-cv-depot-charging-global-market-report

Spend Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/spend-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795